Indirect-response model for the time course of leukopenia with anticancer drugs

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 5, 1998, Pages 511-521

  Minami, Hironobu ^a   Sasaki, Yasutsuna ^b   Saijo, Nagahiro ^b   Ohtsu, Tomoko ^b   Fujii, Hirofumi ^b   Igarashi, Tadahiko ^b   Itoh, Kuniaki ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; PACLITAXEL;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL ARTICLE; CORRELATION FUNCTION; DRUG MECHANISM; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MODEL; PRIORITY JOURNAL;

EID: 0031772402     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90134-5     Document Type: Article

References (34)

1. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol 1990; 8:1739-53.
2. Kobayashi K, Ratain MJ. Individualizing dosing of cancer chemotherapy. Semin Oncol 1993;20:30-42.
3. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53:1037-42.
4. Mick R, Ratain MJ. Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 1991;83:1560-4.
5. Minami H, Ando Y, Sakai S, Shimokata K. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol 1995;13:191-9.
6. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995;1:599-606.
7. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994; 54:427-436.
8. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13: 180-90.
9. Huizing MT, Keung ACF, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993;11:2127-35.
10. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
11. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984;44:5432-8.
12. Minami H, Shimokata K, Saka H, Saito H, Ando Y, Senda K, et al. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J Clin Oncol 1993;11:1602-8.
13. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982;16:146-66.
14. Minami H, Ratain MJ, Ando Y, Shimokata K. Pharmacodynamic modeling of prolonged administration of etoposide. Cancer Chemother Pharmacol 1996;39:61-6.
15. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993;21:457-78.
16. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994;56:406-19.
17. Kong AN, Ludwig EA, Slaughter RL, DiStefano PM, DeMasi J, Middleton E Jr, et al. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther 1989;46: 616-28.
18. Nagashima R, O'Reilly RA, Levy G. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 1969;10:22-35.
19. Tamura T, Sasaki Y, Eguchi K, Shinkai T, Ohe Y, Nishio M, et al. Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. Jpn J Cancer Res 1994; 85:1057-62.
20. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995;22 (suppl 6):16-23.
21. Rothstein G. Hematopoietic cellular production. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, editors. Clinical hematology; vol 1. Philadelphia: Lea & Febiger; 1993. p. 48-54.
22. Boll I, Kühn A. Granulocyotopoiesis in human bone marrow cultures studied by means of by kinematography. Blood 1965;26:449-470.
23. 32). J Clin Invest 1960;39:1481-6.
24. Fliedner TM, Cronkite EP, Killmann SA, Bond VP. Granulocytopoiesis; II: emergence and pattern of labeling of neutrophilic granulocytes in humans. Blood 1964;24:683-700.
25. Cartwright GE, Athens JW, Wintrobe MM. The kinetics of granulopoiesis in normal man. Blood 1964;24:780-803.
26. Athens JW. Neutrophil kinetics and function. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Clinical hematology; vol 1. Philadelphia: Lea & Febiger; 1993. p. 239-47.
27. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9:503-12.
28. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979;25:358-71.
29. Oosterhuis B, ten Berge RJ, Sauerwein HP, Endert E, Schellekens PT, van Boxtel CJ. Pharmacokinetic-pharmacodynamic modeling of prednisolone-induced lymphocytopenia in man. J Pharmacol Exp Ther 1984;229:539-46.
30. Francheteau P, Steimer JL, Dubray C, Lavene D. Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922. J Pharmacokinet Biopharm 1991;19:287-309.
31. Rosner GL, Müller P. Pharmacodynamic analysis of hematologic profiles. J Pharmacokinet Biopharm 1994;22:499-524.
32. Karlsson MO, Port RE, Ratain MJ, Sheiner LB. A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 1995;57:325-34.
33. Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 1998;63:11-25.
34. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7:1333-40.